An Open-label, Long-term Extension Study to Evaluate the Safety, Tolerability and Efficacy of 12 Months of LCZ696 Treatment in Patients With Essential Hypertension
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Amlodipine; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Apr 2013 New trial record
- 27 Mar 2013 Status changed from active, no longer recruiting, to completed, as reported by ClinicalTrials.gov.